Fig. 1: CD155 and CD73 are highly upregulated in GBM and represent negative prognostic factors.
From: synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
A Transcriptional gene expression TCGA data depicting co-expression levels of PVR and NT5E in GBM versus normal tissue; Tumor—n = 163 patients (min: 1.9, max: 5.7, median: 4.1, lower whisker bound: 2.1, upper whisker bound: 5.7, Q1: 3.6, Q3: 4.6), Normal—n = 207 patients (min: 1.1, max: 4.0, median: 3.1, lower whisker bound: 2.1, upper whisker bound: 4.0, Q1: 2.8, Q3: 3.4). B Kaplan-Meier survival plot of PVR/NT5Ehigh/high versus PVR/NT5Elow/low GBM patients (n = 81 patients/group; Mantel-Cox test). C Two-tailed Pearson correlation of PVR and NT5E expression in GBM and normal brain tissue; Tumor—n = 163 patients, Normal—n = 115 patients.D IF tissue array staining for CD155 and CD73 expression in astrocytoma (n = 12 cores), GBM (n = 6 cores), and normal brain tissue (n = 6 cores). E IF scoring of staining in Fig. 1D (ordinary one-way ANOVA, Tukey’s multiple comparison test). F Representative IF tissue array staining of CD155 and CD73 expression from Fig. 1D at 200x magnification. G Venn diagram of no. of patients in PVR/NT5Ehigh/high and PVR/NT5Elow/low groups from TCGA-GBM patient transcriptional gene expression data. (n = 156 patients). H Volcano plot of differentially expressed genes in PVR/NT5Ehigh/high and PVR/NT5Elow/low groups. I Histograms depicting CD73 and CD155 expression on GBM cell lines measured via flow cytometry. Data are presented as mean values +/- SEM. Source data are provided as a Source Data file.
